What it takes for health systems to scale molecular residual disease testing — 3 takeaways

Molecular residual disease testing, which looks for circulating tumor DNA in a patient’s blood to detect cancer recurrence, is extending precision oncology into post-treatment monitoring and survivorship. For health systems, the question is not whether to add another test, but whether the governance, workflows and follow-up pathways exist to use the results consistently. During an […] The post What it takes for health systems to scale molecular residual disease testing — 3 takeaways...